News
ENTA
15.52
+1.24%
0.19
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Enanta Pharmaceuticals, Inc. Shares have gained 26% in the last month but are still down 19%. The company's price-to-sales ratio of 4.4x is lower than the wider Biotechs industry median. However, the company's revenue growth over the last three years has been disappointing. The company is trading at a lower P/S ratio than the industry as a whole.
Simply Wall St · 2d ago
Weekly Report: what happened at ENTA last week (0715-0719)?
Weekly Report · 4d ago
Investors in Enanta Pharmaceuticals (NASDAQ:ENTA) from five years ago are still down 80%, even after 21% gain this past week
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders have lost 12% in the last five years. The share price is up 29% in last month but has fallen 80% over the same period. The company has added US$61m to its market cap in just the last 7 days. Over half a decade the company has reduced its revenue by 25% for each year. We don't think the business justifies a higher share price in the long term.
Simply Wall St · 07/16 10:58
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
NASDAQ · 07/15 14:10
Weekly Report: what happened at ENTA last week (0708-0712)?
Weekly Report · 07/15 09:25
Weekly Report: what happened at ENTA last week (0701-0705)?
Weekly Report · 07/08 09:25
Weekly Report: what happened at ENTA last week (0624-0628)?
Weekly Report · 07/01 09:25
Weekly Report: what happened at ENTA last week (0617-0621)?
Weekly Report · 06/24 09:27
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has US$182.9m of debt, but has more cash than debt. The company made a loss in the last 12 months and has a negative free cash flow of US$113m. The debt is a concern for Enanta, but the company has a strong balance sheet. Enanta has more liquid assets than debt, and has more than enough cash to pay off its debt. However, the company is losing money and is more risky than a company with a long history of profitability.
Simply Wall St · 06/19 11:57
Weekly Report: what happened at ENTA last week (0610-0614)?
Weekly Report · 06/17 09:25
Weekly Report: what happened at ENTA last week (0603-0607)?
Weekly Report · 06/10 09:26
Weekly Report: what happened at ENTA last week (0527-0531)?
Weekly Report · 06/03 09:27
Weekly Report: what happened at ENTA last week (0520-0524)?
Weekly Report · 05/27 09:27
Weekly Report: what happened at ENTA last week (0513-0517)?
Weekly Report · 05/20 09:26
Weekly Report: what happened at ENTA last week (0506-0510)?
Weekly Report · 05/13 09:27
ENANTA PHARMACEUTICALS INC <ENTA.O>: EVERCORE ISI CUTS TARGET PRICE TO $30 FROM $35
Reuters · 05/09 15:26
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Enanta Pharmaceuticals, Inc. Filed its quarterly results last week. The company's shares are down 8.3% following the results. Revenues of US$17,054,000 beat expectations, but statutory losses grew 13% to US$1.47 per share. The consensus estimate for Enanta's revenues in 2024 is for a decline of 4.4%. The consensus price target held steady at US$20.38 for the company.
Simply Wall St · 05/09 11:56
Enanta Pharmaceuticals, Inc. Quarterly Report on Form 10-Q
Press release · 05/09 04:25
Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Enanta Pharmaceuticals (NASDAQ:ENTA) reported revenues of US$17.1m in the second quarter of 2024. The company's shares are down 4.7% from a week ago. Revenue exceeded analyst estimates by 5.2%. Earnings per share missed estimates by 13%. Revenue is forecast to grow 4.2% in the next 3 years.
Simply Wall St · 05/08 11:49
Buy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor Confidence
TipRanks · 05/08 04:37
More
Webull provides a variety of real-time ENTA stock news. You can receive the latest news about Enanta Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).